Literature DB >> 3145297

Inhibitory influence of thyrotropin releasing hormone administration on growth hormone response to low doses of growth hormone-releasing hormone in normal man.

A Zanoboni1, M Gibillini, M R Cucchi, W Zanoboni Muciaccia, C Zanussi.   

Abstract

Literature data show that TRH may have either stimulatory or inhibitory actions on GH release according to pathophysiological conditions of the subject. In view of this dual effect of TRH, we studied the possible interaction of TRH and GRF on GH secretion. Six healthy male volunteers received iv in different occasions and in random order: 1) GRF 0.05 micrograms/Kg; 2) GRF 0.1 micrograms/Kg; 3) GRF 1 microgram/Kg; 4) GRF 0.05 micrograms/Kg + TRH 400 micrograms, simultaneously; 5) GRF 0.05 micrograms/Kg + TRH 20 micrograms, simultaneously; 6) GRF 1 microgram/Kg + TRH 400 micrograms, simultaneously, 7) the vehicle as control treatment. Blood samples were obtained at several time intervals and plasma GH, PRL and TSH were measured by RIA methods. Plasma GH significantly increased in all subjects after all the tested doses of GRF and after the combination of the highest and of the lowest doses of GRF + TRH (treatments 6 and 5). GH responses increased progressively with the dose of GRF administered, even if a clear dose-response relationship could not be demonstrated, owing to the considerable interindividual variability in the responsiveness. The administration of GRF 0.05 micrograms/Kg increased significantly plasma GH levels vs control treatment. The simultaneous administration of a low effective dose of GRF (0.05 micrograms/kg) plus a high dose of TRH (400 micrograms) was able to significantly inhibit the GH secretion elicited by GRF 0.05 micrograms/Kg alone. The other GRF + TRH combinations tested (treatments 5 and 6) did not modify the GH response to the same doses of GRF given alone. Plasma PRL and TSH did not change either after GRF at any dose or after the vehicle.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145297     DOI: 10.1007/bf03349071

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans.

Authors:  K Chihara; Y Kashio; T Kita; Y Okimura; H Kaji; H Abe; T Fujita
Journal:  J Clin Endocrinol Metab       Date:  1986-03       Impact factor: 5.958

Review 2.  Somatocrinin, the growth hormone releasing factor.

Authors:  R Guillemin; P Brazeau; P Böhlen; F Esch; N Ling; W B Wehrenberg; B Bloch; C Mougin; F Zeytin; A Baird
Journal:  Recent Prog Horm Res       Date:  1984

3.  Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture.

Authors:  S Marcovitz; C G Goodyer; H Guyda; R J Gardiner; J Hardy
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

4.  Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.

Authors:  V Jordan; C Dieguez; I Lafaffian; M D Rodriguez-Arnao; A Gomez-Pan; R Hall; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  1986-03       Impact factor: 3.478

5.  Suppression by thyrotropin-releasing hormone (TRH) of human growth hormone release induced by L-dopa.

Authors:  K Maeda; Y Kato; K Chihara; S Ogo; Y Iwasaki
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

6.  Suppression by thyrotropin-releasing hormone (TRH) of growth hormone release induced by arginine and insulin-induced hypoglycemia in man.

Authors:  K Maeda; Y Kato; K Chihara; S Ohgo; Y Iwasaki
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

7.  Growth hormone release following thyrotrophin-releasing hormone injection into patients with anorexia nervosa.

Authors:  K Maeda; Y Kato; N Yamaguchi; K Chihara; S Ohgo
Journal:  Acta Endocrinol (Copenh)       Date:  1976-01

8.  Responses to thyrotropin-releasing hormone in patients with renal failure and after infusion in normal men.

Authors:  D Gonzalez-Barcena; A J Kastin; D S Schalch; M Torres-Zamora; E Perez-Pasten; A Kato; A V Schally
Journal:  J Clin Endocrinol Metab       Date:  1973-01       Impact factor: 5.958

9.  Increase in plasma growth hormone levels following thyrotropin-releasing hormone injection in children with primary hypothyroidism.

Authors:  R Collu; G Leboeuf; J Letarte; J R Ducharme
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

10.  Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women.

Authors:  M C Gelato; O H Pescovitz; F Cassorla; D L Loriaux; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.